Cargando…

Cure in metastatic breast cancer

Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Westphal, Theresa, Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132799/
https://www.ncbi.nlm.nih.gov/pubmed/30220923
http://dx.doi.org/10.1007/s12254-018-0426-9
_version_ 1783354388651180032
author Westphal, Theresa
Gampenrieder, Simon Peter
Rinnerthaler, Gabriel
Greil, Richard
author_facet Westphal, Theresa
Gampenrieder, Simon Peter
Rinnerthaler, Gabriel
Greil, Richard
author_sort Westphal, Theresa
collection PubMed
description Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several case series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defense by immuno-oncologic drugs can achieve long-lasting tumor control. So far, unfortunately, checkpoint inhibitors as monotherapy have led to responses only in a small percentage of patients with metastatic breast cancer. This short review summarizes available data on long-lasting remissions and potential cure in metastatic breast cancers. It describes and discusses data on locoregional treatment, chemo-, antibody- and immunotherapy and tries to select individual patients for whom a multidisciplinary treatment approach with curative intention might be an option to achieve long-term survival.
format Online
Article
Text
id pubmed-6132799
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-61327992018-09-13 Cure in metastatic breast cancer Westphal, Theresa Gampenrieder, Simon Peter Rinnerthaler, Gabriel Greil, Richard Memo Short Review Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several case series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defense by immuno-oncologic drugs can achieve long-lasting tumor control. So far, unfortunately, checkpoint inhibitors as monotherapy have led to responses only in a small percentage of patients with metastatic breast cancer. This short review summarizes available data on long-lasting remissions and potential cure in metastatic breast cancers. It describes and discusses data on locoregional treatment, chemo-, antibody- and immunotherapy and tries to select individual patients for whom a multidisciplinary treatment approach with curative intention might be an option to achieve long-term survival. Springer Vienna 2018-08-17 2018 /pmc/articles/PMC6132799/ /pubmed/30220923 http://dx.doi.org/10.1007/s12254-018-0426-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Review
Westphal, Theresa
Gampenrieder, Simon Peter
Rinnerthaler, Gabriel
Greil, Richard
Cure in metastatic breast cancer
title Cure in metastatic breast cancer
title_full Cure in metastatic breast cancer
title_fullStr Cure in metastatic breast cancer
title_full_unstemmed Cure in metastatic breast cancer
title_short Cure in metastatic breast cancer
title_sort cure in metastatic breast cancer
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132799/
https://www.ncbi.nlm.nih.gov/pubmed/30220923
http://dx.doi.org/10.1007/s12254-018-0426-9
work_keys_str_mv AT westphaltheresa cureinmetastaticbreastcancer
AT gampenriedersimonpeter cureinmetastaticbreastcancer
AT rinnerthalergabriel cureinmetastaticbreastcancer
AT greilrichard cureinmetastaticbreastcancer